Quinone oxidoreductase-2-mediated prodrug cancer therapy.
|Abstract||DNA-damaging agents are widely used in cancer treatment despite their lack of tumor specificity. Human NQO2 (quinone oxidoreductase-2) is an atypical oxidoreductase because no endogenous electron donor has been identified to date. The enzyme converts CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide], in the presence of the synthetic nicotinamide cofactor analog EP0152R, to a cytotoxic bifunctional alkylating agent. NQO2 activity in hepatocellular t ... [truncated at 450 characters in length]|
|Author||Middleton, Mark R; Knox, Richard; Cattell, Emma; et al|